source
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.BioPharma Dive · 2mo ago↗ source
- The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayHow much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The FD…Endpoints · 2mo ago↗ source
- Epigenetic editing shows promise against chronic hep B infectionsA new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therape…